Omarigliptin
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
1226781-44-7CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2MKMPWKUAHLTIBJ-ISTRZQFTSA-NOmarigliptin is a pyrrolopyrazole.
1226781-44-7DTXSID70153678CHEMBL2105762CHEBI:134735Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Alimentary tract and metabolism -> Drugs used in diabetes
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H373 (100%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
P260, P319, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 36 reports by companies from 2 notifications to the ECHA C&L Inventory.
説明Merck earned its first global approval for omarigliptin in Japan in 2015, and phase III development is ongoing in other countries around the globe for this interesting small molecule DPP-4 inhibitor. Interestingly, while most DPP-4 inhibitors used to treat type 2 DM require daily administration, omarigliptin is a weekly treatment. The process-scale synthesis of omarigliptin has been nicely described in an October 2015 paper from the Merck process group.
使用Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.
読み込み中…